Copyright: ©Author(s) 2026.
World J Gastroenterol. Nov 14, 2026; 32(42): 119693
Published online Nov 14, 2026. doi: 10.3748/wjg.119693
Published online Nov 14, 2026. doi: 10.3748/wjg.119693
Table 2 Clinical and biochemical remission, median (interquartile range)/n (%)
| Outcome | Baseline | 12 weeks | 6 months | 12 months | P value |
| HBI | 8 (5-11) | 4 (3-8) (< 0.001)1 | 5 (3-8) (0.003)1 | 4 (3-8) (< 0.001)1 | < 0.001 |
| CRP (mg/L) | 4.8 (2.9-12.1) | 4.0 (2.0-8.2) | 4.0 (2-10) | 3.9 (1.6-7.4) | 0.268 |
| FC (μg/g) | 1113.5 (437-2200) | 807.5 (274.0-1500.3) | 840.0 (336.5-1488.0) | 1063.5 (341.3-2200.0) | 0.103 |
| Clinical remission | 41 (20.2) | 89 (48.6) (< 0.001)2 | 56 (46.3) (< 0.001)2 | 22 (48.9) (0.016)2 | |
| Clinical-biochemical remission | 9 (4.4) | 16 (8.7) | 8 (6.6) | 3 (6.7) | |
| Steroid-free remission | 75 (41.0) | 53 (43.8) | 19 (42.2) |
- Citation: Caballero-Mateos AM, Valdés-Delgado T, Olmedo-Martín R, Romero-Cara P, Martín-Rodríguez MDM, Lancho Muñoz A, Moreno-Barrueco M, Gijón-Villanova R, Fernández-Moreno N, Rodríguez-González FJ, Hernández-Martínez Á, Trapero-Martínez AM, Bejarano-García A, Benitez Cantero JM, Mata-Perdigón FJ, Sáez-Díaz A, Argüelles-Arias F. Real-world effectiveness and safety of risankizumab in multirefractory Crohn’s disease: A multicenter AIRIS-Crohn registry analysis. World J Gastroenterol 2026; 32(42): 119693
- URL: https://www.wjgnet.com/1007-9327/full/v32/i42/119693.htm
- DOI: https://dx.doi.org/10.3748/wjg.119693